The U.S. Food and Drug Administrated (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) status to AAV-GAD, MeiraGTx’s gene therapy for Parkinson’s disease, the company has announced. The designation was granted based on data from three clinical studies showing the treatment eased motor symptoms and improved the quality…
Two University of Michigan-Flint doctorate students received a $50,000 grant to support diversity among exercise providers offering care to people with Parkinson’s disease. The grant, from The Michigan Health Equity Challenge, will help the pair’s Move to Represent initiative train 10 physical and occupational therapists of color to…
Using advanced diagnostic tools — such as different types of brain scans and methods that employ artificial intelligence (AI) — may help detect early signs of Parkinson’s that precede the onset of the disease’s motor symptoms, according to a new review study. The researchers noted that employing these AI-based…
The Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program, which trains specialists in improving access to Parkinson’s disease care. The program provides funding each year for medical centers to train physicians to become Parkinson’s specialists.
The dysregulation of RNA editing within astrocytes (neuron-supporting cells) seems to induce chronic inflammation and ultimately contributes to the loss of nerve cells in people with Parkinson’s disease, according to a recent study. This dysregulation is triggered by alpha-synuclein clumping, which is a characteristic feature of Parkinson’s. RNA editing…
Physical exercise, avoiding falls, and the importance of providing support to caregivers were the focus of the 10th UAMS Parkinson’s symposium hosted last month by the University of Arkansas for Medical Sciences (UAMS), where the latest advances in diagnosing and treating people with Parkinson’s disease and atypical parkinsonism…
Low-dose psilocybin, a naturally occurring psychedelic compound, may be a promising therapy for mood issues including depression and anxiety in people with Parkinson’s disease, according to data from a pilot Phase 2 clinical trial. In addition to significant reductions in depression and anxiety, results from the trial (NCT04932434)…
Blocking the inflammatory protein ASC with IC 100, ZyVersa Therapeutics’ experimental therapy to reduce inflammation, prevented the activation of the inflammasome in microglia — the brain’s resident immune cells — and the start and perpetuation of an inflammatory response. That’s according to results from a study announced by the…
The STING protein, which has been linked to cell damage and brain inflammation — two known contributing factors to Parkinson’s disease and other neurodegenerative diseases — has a dual function, a study found. The researchers said their finding could have implications for treating Parkinson’s and other neurodegenerative diseases. Lysosomes,…
A new artificial intelligence (AI) tool may help predict the structure of amyloid fibrils, that is, misfolded protein fibers that accumulate in the brain of people with neurodegenerative diseases such as Parkinson’s. Called Ribbonfold, the tool is designed to address the complex and variable structures of misfolded proteins by…
Get regular updates to your inbox.
